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ORIGINAL ARTICLE
Short- and long-term impact of remifentanil on thermal
detection and pain thresholds after cardiac surgery
A randomised controlled trial
Sjoerd de Hoogd, Abraham J. Valkenburg, Eric P.A. van Dongen, Edgar J. Daeter,
Joost van Rosmalen, Albert Dahan, Dick Tibboel and Catherijne A.J. Knibbe
BACKGROUND The clinical relevance of the suggested
hyperalgesic effects of remifentanil is still unclear, especially
in the long term.
OBJECTIVE The current study evaluated the impact
of remifentanil on thermal thresholds 3 days and
12 months after surgery, measured with Quantitative Sen-
sory Testing.
DESIGN A single-blind, randomised controlled trial.
SETTING A tertiary care teaching hospital in TheNetherlands,
from 2014 to 2016.
PATIENTS A total of 126 patients aged between 18 and 85
years, undergoing cardiothoracic surgery via sternotomy
(coronary artery bypass grafts and/or valve replacement)
were included. Exclusion criteria were BMI above
35 kgm2, history of cardiac surgery, chronic pain condi-
tions, neurological conditions, allergy to opioids or paracet-
amol, language barrier and pregnancy.
INTERVENTIONS Patients were allocated randomly to
receive intra-operatively either a continuous remifentanil infu-
sion or intermittent intra-operative fentanyl as needed in addi-
tion tostandardisedanaesthesiawith propofol and intermittent
intravenous fentanyl at predetermined time points.
MAIN OUTCOME MEASURES Warm and cold detection
and pain thresholds 3 days and 12 months after surgery. In
addition the use of remifentanil, presence of postoperative
chronic pain, age, opioid consumption and pre-operative
quality of life were tested as a predictor for altered pain
sensitivity 12 months after surgery.
RESULTS Both warm and cold detection, and pain thresh-
olds, were not significantly different between the remifentanil
and fentanyl groups 3 days and 12 months after surgery
(P>0.05). No significant predictors for altered pain sensi-
tivity were identified.
CONCLUSION Earlier reports of increased pain sensitivity
1 year after the use of remifentanil could not be confirmed
in this randomised study using Quantitative Sensory
Testing. This indicates that remifentanil plays a minor
role in the development of chronic thoracic pain. Still,
the relatively high incidence of chronic thoracic pain and
its accompanying impact on quality of life remain chal-
lenging problems.
TRIAL REGISTRATION The study was registered at
EudraCT (ref: 2013-000201-23) and ClinicalTrials.gov
(https://clinicaltrials.gov/ct2/show/NCT02031016).
Published online 11 September 2018
Introduction
Chronic postsurgical pain – defined as the persistence of
pain at least 3 months after a surgical procedure – has
been reported to occur in 25 to 55% of patients after
cardiac surgery.1–4 It is known to have a negative impact
on quality of life (QoL) and daily activities, contributing
to increasing public health costs and lost productivity.5–7
Chronic postsurgical pain is considered to be mostly
neuropathic and associated with sensory abnormalities.8
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Altered pain sensitivity in patients can be identified using
Quantitative Sensory Testing (QST)9,10 by exposing
patients to external stimuli and thereby mapping their
pain and detection thresholds.11 Studies report a pre-
dictive value of increased pain sensitivity measured
with QST for the development of acute postoperative
pain12 in contrast to no predictive value of response to
analgesic treatment.13 Lundblad et al.14 showed that
pre-operative lower electrical pain threshold predicted
higher pain intensity 18 months after total knee replace-
ment. A recent cohort study revealed that lower pain
pressure thresholds with heightened widespread pain
sensitivity before surgery were associated with signifi-
cantly higher pain severity at 12 months after total hip
replacement.15
Evidence is growing for opioid-induced hyperalgesia
being another external factor besides surgery itself that
could influence pain perception.16 Remifentanil is a fast-
acting opioid and favoured for its pharmacokinetic pro-
file, but is also associated with postoperative hyperalge-
sia.16–18 A retrospective study in cardiac patients
suggested that remifentanil use was associated with
chronic postoperative pain 12 months after surgery.19 A
recent randomised controlled trial (REFLECT trial)
showed no significant difference in the incidence of
chronic thoracic pain 1 year after surgery between
patients receiving either intra-operative remifentanil or
fentanyl [11 (17.5%) vs. 12 (19.7%), P¼ 0.817].20 How-
ever, a significant difference was found at 3-month fol-
low-up, when patients treated with remifentanil reported
postoperative pain significantly more often compared
with the control group [32 (50.8%) vs. 21 (33.3%),
P¼ 0.049]. These patients also consumed significantly
more opioids compared with the remifentanil group 48 h
after surgery (P¼ 0.047).20
As part of the REFLECT trial, thermal detection and
pain thresholds were measured before surgery, and 3 days
after and 12 months after surgery. This study aims to
investigate the effect of remifentanil on these thermal
detection and pain thresholds, and to identify whether
altered thresholds predict the development of chronic
postsurgical pain after cardiac surgery.
Methods
The prospective and randomised controlled REFLECT
trial was approved by the local research ethics committee
(VCMO St. Antonius Hospital, Chairperson V. Deneer,
ref: R13.013) on 8 August 2013, and registered with
EudraCT (ref: 2013-000201-23). Written informed con-
sent was obtained from all patients before the cardiotho-
racic surgical procedure.
Patients aged 18 to 85 years were eligible if they
were scheduled for elective cardiac surgery via ster-
notomy (coronary artery bypass grafting and/or valve
replacement). Exclusion criteria were: pregnancy or
breastfeeding; language barrier; history of drug abuse;
neurological conditions such as peripheral neuropathy
or fibromyalgia; known remifentanil, fentanyl, mor-
phine or paracetamol allergy; BMI above 35 kg m2;
prior cardiac surgery (re-operations); and chronic pain
condition. Patients with a BMI above 35 kg m2 were
excluded because altered sensory thresholds have been
reported compared with nonobese patients.21
The study protocol has been published previously.22 All
patients were scheduled for cardiac surgery with a
classical full sternotomy approach, so no minimally
invasive surgery was performed. After a standardised
induction protocol, both groups received a continuous
infusion of propofol (starting dose 200 to 300 mg h1)
and intermittent intravenous fentanyl (200 to 500mg) at
predetermined times (before incision, at sternotomy, at
aortic cannulation and at opening of the pericardium).
Patients were allocated randomly to either a remifenta-
nil or a fentanyl study arm and were blinded to treat-
ment group allocation. The remifentanil arm received a
continuous remifentanil infusion based on ideal body
weight starting at 0.15mg kg1 min1. The fentanyl arm
received additional fentanyl boluses (200 to 500mg)
as needed.
Thirty minutes before the anticipated end of surgery,
each patient received a fixed dose of intravenous mor-
phine of 10 mg, or, when indicated 5 mg. Immediately
after surgery, paracetamol (1 g orally or intravenously)
was given four times a day together with a continuous
infusion of morphine (starting dose 2 mg h1), which was
adapted individually on the guidance of the patient’s
numerical rating scale (NRS) pain scores according to the
standard pain protocol of the hospital with a target NRS
value of less than 4.23 On the ward, the continuous
infusion of morphine was replaced by 2.5 to 10 mg of
intravenous morphine as needed as per protocol.
One day before surgery, 3 days after surgery and
12 months after surgery, patients underwent Quantitative
Sensory Testing (QST) in a quiet room pre-operatively
and on the ward postoperatively. Thermal detection and
pain thresholds were assessed with the Thermal Sensory
Analyser (TSA; Type II Medoc Ltd. Advanced Medical
Systems, Ramat Yishai, Israel) using previously pub-
lished protocols.24,25 The thermode (30 30 mm) stimu-
lating surface was placed on the volar side of the
nondominant forearm. The applied temperature ranged
from 0 to 50 8C, which is safe and nondamaging to the
skin. First, the subject’s visual motor reaction time was
measured with open-source software (http://delphiforfu-
n.org/Programs/Reaction_times.htm). Next, detection
and pain thresholds for cold and heat were determined
with the method of limits.26 The detection thresholds for
cold and heat were examined by gradually decreasing or
increasing, respectively, the baseline temperature of
32 8C at a rate of 1 8C s1. The subject was instructed
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to press the button as soon as the cold or heat stimulus
was felt, after which the temperature normalised to
baseline temperature. Then, the subject was instructed
to press the button if the thermode started to feel painful
– either for cold or heat. For the determination of pain
thresholds, the temperature was reversed at a rate of
10 8C s1 after the button was pressed. A minimum of
two tests served as rehearsals. Detection and pain thresh-
olds were calculated as the means of the four following
tests. If the button was not pressed before 0 or 50 8C was
reached, the test was automatically terminated. In this
case, the pain thresholds were set at 0 and 50 8C, respec-
tively. All QST tests in this study were performed by the
same researcher.
Postoperatively, a nurse on the ICU/Post Anaesthesia
Care Unit or the ward recorded pain scores using the
visual analogue scale three times daily and opioid con-
sumption during the first 72 h.
After discharge from the hospital, subjects were asked to
complete a questionnaire 3, 6 and 12 months after sur-
gery. This questionnaire has been described previously27
and is based on the Brief Pain Inventory28 containing
questions about pain (perception, location, intensity). In
addition, QoL was self-reported with the short form-12
health status instrument at the same time points.
Statistical analysis
Continuous data are presented as median [interquartile
range] and analysed using the Mann–Whitney U test, or
as meanSD and analysed using Student’s t test, where
appropriate. Normal distribution of the variables was
assessed with the Kolmogorov–Smirnov test and histo-
grams. Categorical data were compared between treat-
ment groups using x2 tests. Independent of treatment
group, the QST outcomes and reaction times at the
follow-up time points were compared with baseline using
the Wilcoxon signed-rank test. In a multivariate analysis
of the QST data, the following independent variables
were included for warm and cold detection and pain
thresholds: treatment condition (remifentanil vs. fenta-
nyl), baseline QST measurement, age, opioid consump-
tion in the first 72 h, chronic pain 12 months after surgery,
pre-operative QoL. Reaction time was only included in
the analysis of the reaction time-dependent thresholds
for detection of heat and cold. A robust regression analysis
with MM estimation was used to account for the fact
that the model residuals were not normally distributed.
The weight function was the Tukey bisquare estimator.
P values (two-sided) of less than 0.05 were considered
statistically significant. Data were analysed in IBM
SPSS Statistics version 24 (Chicago, Illinois, USA) and
R-statistics version 3.0.1 (Vienna, Austria).
Power
A sample size calculation was performed for the primary
endpoint, chronic thoracic pain and based on the findings
of a previous study.19 This study found, 1 year after
cardiac surgery, an incidence of chronic pain of approxi-
mately 10% in the fentanyl study arm and 30% in the
remifentanil arm. This resulted in a total number of
patients of 117, with a power of 0.80 and a two-sided
significance level of 0.05. Taking into account a mortality
rate of 8% 1 year after surgery,19 the total number of
patients is 126, which results in 63 subjects per arm.
Results
A total of 555 patients were screened for eligibility; 201
patients did not meet the inclusion criteria, 96 patients
refused to participate and 132 patients were excluded for
other reasons (n¼127 logistic reasons and n¼5 unknown).
In total, 126 patients were included (Fig. 1). Detection
thresholds and pain thresholds were measured in all 126
patients one day before surgery. After surgery, 124 sub-
jects were tested (two had been transferred to other
hospitals). One year after surgery, QST measurements
were taken in 112 patients. Two patients had died, other
patients were not able to visit the hospital again or contact
was lost (Fig. 1). An overview of patient characteristics is
shown in Table 1. More details on the primary outcome
of the study can be found in the original article.20
Three days after surgery, no significant differences in
detection thresholds were found between the groups
(warm median 8C [IQR] 30.2 [29.6 to 30.7] vs. 29.8
[28.6 to 30.7] P¼ 0.320; cold: 35.2 [34.6 to 36.5] vs.
35.7 [34.6 to 36.9], P¼ 0.31). Pain thresholds were not
significantly different between groups (heat pain median
8C [IQR] 47.0 [44.2 to 48.6] vs. 46.8 [43.7 to 49.0],
P¼ 0.87; cold pain median 8C [IQR] 10.1 [2.8 to 18.4]
vs. 8.6 [1.3 to 20.1], P¼ 0.86). Twelve months after
surgery, no significant differences in detection and pain
thresholds (median 8C [IQR]) were found between the
groups (warm detection: 35.2 [34.5 to 36.3] vs. 35.3 [34.5
to 36.9], P¼ 0.91; cold detection: 30.4 [29.4 to 30.7] vs.
30.3 [29.5 to 30.7], P¼ 0.70; heat pain: 47.7 [45.4 to 49.2]
vs. 48.1 [45.7 to 49.4], P¼ 0.88; cold pain: 6.6 [1.7 to 18.3]
vs. 4.8 [1.6 to 13.5], P¼ 0.65) (Fig. 2).
Independent of group allocation, three days after surgery
pain thresholds for heat and cold (median 8C [IQR]) were
lower than baseline values (heat: 46.9 [43.8 to 48.7] vs.
48.1 [46.4 to 49.1], P< 0.001; cold: 9.5 [1.8 to 19.2] vs. 5.6
[1.5 to 15.3]; P¼ 0.002). This could not be explained by
the reaction time, as this was significantly higher 3 days
postsurgery compared with baseline (0.308 0.1 vs.
0.380 0.1; P< 0.001). Pain thresholds returned back
to baseline levels 12 months after surgery (heat baseline:
48.1 [46.4 to 49.1] vs. 12 months: 48.0 [45.7 to 49.3],
P¼ 0.782; cold baseline: 5.7 [1.5 to 15.2] vs. 12 months:
4.9 [1.7 to 15.5], P¼ 0.588) (Supplemental data content
Table S1, http://links.lww.com/EJA/A173).
Twelve months after surgery, detection thresholds for
heat and cold (median 8-C [IQR]) were lower than
34 de Hoogd et al.
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baseline values (heat: 35.2 [34.5 to 36.4] vs. 35.8 [34.7 to
37.3]; P¼ 0.047; cold: 30.4 [29.4 to 30.7] vs. 29.9 [28.9 to
30.6]; P¼ 0.045) (Supplemental data content Table S1,
http://links.lww.com/EJA/A173).
Regression estimates for the four QST modalities mea-
sured 12 months after surgery are shown in Table 2.
In the model, treatment condition (remifentanil or
fentanyl), presence of chronic pain 12 months after
surgery, age, opioid consumption and pre-operative
QoL were not significantly associated with altered pain
sensitivity measured with QST. Baseline values were
associated with the follow-up values for cold detection
and pain thresholds 12 months after surgery. The regres-
sion estimates for detection and pain thresholds mea-
sured 3 days after surgery also revealed no significant
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Fig. 1
Assessed for eligibility
n = 555
Patients excluded n = 429
 Did not meet inclusion criteria n = 201
 Refused to participate n = 96
 Other reasons n = 132
Lost to follow up n = 9
 3 days after surgery
  2 transferred
 12 months after surgery
  2 deceased
  5 not able to visit hospitalBaseline QST
 n = 63 (100%)
3 days after surgery
 n = 63 (100%)
12 months after surgery
 n = 56 (88.9%)
Baseline QST
 n = 63 (100%)
3 days after surgery
 n = 61 (96.8%)
12 months after surgery
 n = 56 (88.9%)
Lost to follow up n = 7
 12 months after surgery
  2 contact was lost
  5 not able to visit hospital
Randomised
n = 126
Fentanyl
n = 63
Remifentanil
n = 63
Flow chart of study.
Table 1 Patient and peri-operative characteristics
Fentanyl, nU63 Remifentanil, nU63 P
Male sex 57 (90) 58 (92) 0.752
Age (years) 667.6 629.0 0.006
BMI (kgm2) 28.03.1 27.53.6 0.471
Pre-operative NRS 0 [0 to 0] 0 [0 to 0] 0.765
Pre-operative quality of life
PCS 49.3 [43.3 to 53.1] 47.6 [39.6 to 54.3] 0.666
MCS 51.3 [46.1 to 57.2] 50.4 [46.8 to 54.3] 0.212
Type of surgery 0.389
CABG 51 (81.0) 49 (77.8)
Valve 9 (14.3) 7 (11.1)
Combination 3 (4.8) 7 (11.1)
EuroSCORE 3 [2 to 4] 2 [0 to 4] 0.035
Intra-operative characteristics
Duration of general anaesthesia (min) 218.649.0 233.472.1 0.179
Duration of surgery (min) 187.446.7 198.170.8 0.317
Cross-clamp time (min) 51.421.3 59.632.5 0.095
Propofol (mg kg1) 12.0 [9.7 to 16.6] 12.6 [9.5 to 15.4] 0.913
Fentanyl (mg kg1) 26.1 [19.4 to 31.4] 19.4[15.4 to 27.2] 0.003
Remifentanil (mg kg1) NA 22.9 [18.1 to 30.9] NA
Continuous data are presented as meanSD or median [interquartile range], and categorical data are presented as number (%). CABG, coronary artery bypass grafting;
EuroSCORE, European System for Cardiac Operative Risk Evaluation; IQR, interquartile range; MCS, mental composite score; NA, nonapplicable; NRS, numerical rating
scale; PCS, physical composite score.
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predictors for altered pain sensitivity. For all four modal-
ities, baseline measurements showed significant correla-
tion with the measurement 3 days after surgery after
adjustment for other variables (Supplemental data con-
tent Table S2, http://links.lww.com/EJA/A173).
Discussion
Several studies of widely different design found that
remifentanil use during surgery correlated with more
postoperative pain and higher opioid consumption in
the short term.16,18 The aim of this study was to deter-
mine whether the intra-operative use of remifentanil
would have any effect on thermal detection and pain
thresholds in the short and longer term after surgery.
Statistical analysis showed no significant differences in
detection and pain thresholds in patients treated with
remifentanil or fentanyl 3 days and 1 year after cardiac
surgery. In a regression analysis, no other significant
predictors for altered pain sensitivity 1 year after surgery
were present.
The primary analysis of the REFLECT trial showed that
patients receiving remifentanil during cardiac surgery
needed more opioids after surgery to reach adequately
low pain scores. In addition, 3 months after surgery, these
patients also reported more pain related to the surgery, a
difference that was not found 1 year after surgery.20
These potential short-term effects of remifentanil did
not result in significant differences in pain and detection
thresholds 3 days after surgery. In line with the reported
pain scores, sensory thresholds 1 year after surgery were
also not significantly different between the two groups.
Regarding the effect of remifentanil on QST modalities
directly after surgery, one study showed an increase in
pain sensitivity to tactile stimuli in the high-dose remi-
fentanil group during 2 days after surgery.29 Another
study found a decrease in pressure pain tolerance
36 de Hoogd et al.
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thresholds directly after eye surgery in the high-dose
remifentanil group, whereas thermal thresholds showed
no effect.30 In the current study, thermal pain thresholds
3 days after surgery had significantly decreased from
baseline values in both treatment groups. This could
indicate higher sensitivity for heat and cold sensation 3
days after the surgery, despite the administration of
analgesics. A confounding factor is that patients in the
remifentanil group received more opioids in the first 48 h
compared with the fentanyl group. However, patients in
both groups had received opioids and decreased thresh-
olds were found in both groups. One year after surgery,
pain thresholds had returned to baseline values. No
significant differences in detection and pain thresholds
were found between the remifentanil and fentanyl
groups.
To our knowledge, no data is available regarding the
intra-operative use of remifentanil and its effect on
hyperalgesia measured with QST in the longer term.
Despite being another concept than hyperalgesia, with
different definition and mechanism, one study measured
allodynia (i.e. pain due to a stimulus that does not usually
provoke pain) 1 month after remifentanil administration.
In 38 cardiac surgery patients, an increased area of
mechanical allodynia around the incisional site was found
in the patients receiving high dose remifentanil and
postsurgical epidural analgesia.31 This study illustrates
that remifentanil use during surgery can have an impact
on sensory thresholds in the longer term. Our study
assessed only secondary hyperalgesia, which is thought
to derive from central sensitisation to pain.32 No differ-
ences in thermal thresholds were found before and 12
months after surgery. As patients in the remifentanil
group directly after surgery had an increased need for
opioids and reported more thoracic pain 3 months after
surgery, it was encouraging to find that after 12 months
there were no significant differences in patient-reported
outcomes or in sensory thresholds. This implies that the
clinical relevance of remifentanil-induced (secondary)
hyperalgesia on sensory perception in the longer term
is minimal or possibly self-limiting.
The possible mechanisms of remifentanil-induced
hyperalgesia are still controversial. The ultrashort half-
life of remifentanil together with inadequate and timely
administration of long-acting analgesics could be an
explanation for the increase in pain scores and in the
use of postoperative opioids after the use of remifentanil.
However, in our and other studies in which long-acting
opioids were administered in a timely manner for
bridging the possible opioid gap, increases in pain param-
eters directly after surgery have been reported.17,18
This suggests that there are more potential causes of
hyperalgesia.
On a molecular level, it has been suggested that changes
in neuroplasticity in the peripheral and central nervous
system may lead to central sensitisation of nociceptive
pathways, resulting in reduced nociceptive thresholds.33
Although multiple mechanisms are postulated, the
N-methyl-D-aspartate (NMDA) receptor appears to play
a key role in the development of opioid-induced hyper-
algesia. This receptor is involved in neuroplasticity and
long-term potentiation, and affected by remifentanil
through multiple pathways.34–36 It is unknown what
the mechanism is regarding a prolonged remifentanil
effect, but animal data showed a potential role of protein
kinase C zeta (PRCKZ), which appears to plays a role in
the development of prolonged remifentanil-induced
hyperalgesia. PRCKZ is involved in long-term potentia-
tion and pain memory, peaks 2 days after cessation of
remifentanil infusion and returns to baseline level after 7
days. Blockade of this substance reversed postinfusion
hyperalgesia induced by remifentanil.37 The involve-
ment of the NMDA receptor and its role in neuroplas-
ticity could possibly explain the transient negative
impact of remifentanil 3 months after surgery. This is
only hypothesising, and more research is needed to
identify the complex pathways that are involved in the
acute and prolonged effects of remifentanil.
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Table 2 Robust regression estimates of remifentanil, with
adjustment for different covariates detection and pain thresholds
12 months after surgery
Modality Estimate 95% CI P
Detection threshold for cold
Intercept 25.6 23.8 to 27.5 <0.001
Remifentanil 0.01 0.26 to 0.27 0.955
Baseline detection threshold cold (8C) 0.15 0.12 to 0.18 <0.001
Age (years) 0.00 0.02 to 0.01 0.667
Opioid consumption first 72 h (mg) 0.00 0.01 to 0.01 0.897
Chronic pain after 1 year 0.09 0.27 to 0.46 0.612
QoL pre-operative 0.01 0.03 to 0.04 0.737
Reaction time (s) 0.44 1.26 to 2.13 0.611
Detection threshold for heat
Intercept 26.5 20.6 to 32.3 <0.001
Remifentanil 0.36 0.16 to 0.88 0.178
Baseline detection threshold heat (8C) 0.23 0.09 to 0.38 0.002
Age (years) 0.001 0.03 to 0.03 0.932
Opioid consumption first 72 h (mg) 0.01 0.00 to 0.02 0.259
Chronic pain after 1 year 0.30 0.40 to 0.99 0.401
QoL pre-operative 0.003 0.04 to 0.05 0.897
Reaction time (s) 0.09 3.96 to 3.78 0.964
Pain threshold for cold
Intercept 0.23 10.6 to 10.1 0.965
Remifentanil 1.06 3.70 to 1.58 0.427
Baseline pain threshold cold (8C) 0.82 0.57 to 1.07 <0.001
Age (years) 0.01 0.16 to 0.13 0.853
Opioid consumption first 72 h (mg) 0.01 0.06 to 0.03 0.591
Chronic pain after 1 year 0.56 2.78 to 3.90 0.741
QoL pre-operative 0.07 0.09 to 0.24 0.363
Pain threshold for heat
Intercept 22.9 8.5 to 37.3 0.002
Remifentanil 0.11 0.92 to 0.70 0.791
Baseline pain threshold heat (8C) 0.53 0.22 to 0.84 0.001
Age (years) 0.01 0.05 to 0.06 0.746
Opioid consumption first 72 h (mg) 0.004 0.01 to 1.02 0.615
Chronic pain after 1 year 0.25 1.51 to 1.02 0.702
QoL pre-operative 0.02 0.07 to 0.03 0.422
QoL, quality of life questionnaire.
Eur J Anaesthesiol 2019; 36:32–39
The reported incidence of chronic thoracic pain 1 year
after surgery in this study is 18.9% overall and not
significantly different between study groups. Previous
studies have reported 1-year incidences around 25%.2–4
Pharmacological interventions for preventing chronic
pain are still not convincing, with a modest effect of
ketamine as most promising.38 Other drugs, for example
pregabalin, seem to have no added value.39
QST is widely used to diagnose and monitor chronic and
neuropathic pain disorders.11 However, in routine clinical
practice, QST is not well established in relation to
postoperative pain because results are conflicting or
not convincing, and measurements are time-consuming.
As mentioned above, some studies report a predictive
value of pre-operative QST measurements, whereas
others find no such association.40,41 Our study shows
no distinctive added value of measuring thermal detec-
tion and pain thresholds for evaluating chronic postsur-
gical pain in patients 1 year after cardiac surgery. In
addition to thermal thresholds, other methods have been
used to study chronic postoperative pain. Measurement
of diffuse inhibitory noxious control (DNIC) gives a
dynamic view of the pain processing system.42 Patients
with impaired conditioned pain modulation or DNIC
were found to have a greater likelihood of developing
chronic postoperative pain.11,43 Pre-operative DNIC
explained around 25% of the variability in chronic post-
operative pain intensity, whereas the numbers of static
thresholds were below 6%. It is possible that the use of
multiple modalities of QST, such as pressure, electrical
thresholds or measuring DNIC, provides more informa-
tion, but the more extensive and time-consuming, the
more difficult is the use of QST protocols in daily
practice. In addition, static QST thresholds such as
detection and pain thresholds appear to have sufficient
test–retest reliability.44 Our study measured thermal
detection and pain thresholds 3 days and 12 months after
surgery and was performed to assess the potential of QST
for application in clinical practice. After all, it takes only
16 to 18 min per measurement. Still, gathering pieces of
evidence of the complicated puzzle of postoperative pain
management adds to the final goal of reducing incidences
of short-term and chronic postoperative pains. Recently,
it has been suggested that patients with peripheral neu-
ropathic pain can be divided into subgroups on the basis
of sensory profiles, potentially increasing the response to
pharmacological treatment.45 Whether QST can also play
a role in the management of postoperative pain is a field
for future research.
Limitations
First, the ideal study design should be double-blind and
contain no other opioid besides remifentanil. Patients in
the remifentanil group also received fentanyl during
surgery as this was standard care in our hospital and it
is not, in our opinion, in patients’ best interest to use a
high-dose remifentanil as the single analgesic during this
prolonged procedure because of the risk of increased
immediate postoperative pain. Of note, an earlier obser-
vational study using the same regimens suggested that
remifentanil was predictive for chronic thoracic pain 1
year after the study.19 However, it has to be taken into
account that patients in the remifentanil group also
received fentanyl during surgery and the possibility that
fentanyl does not contribute to the outcome of this study
cannot be excluded.
Second, the design of this study is single-blind. In our
opinion, blinding only patients to study treatment was
enough to ensure a valid outcome of the primary and
secondary outcomes because patients self-reported pain
scores and were in control of QST measurements.
Third, the QST-battery was limited to thermal stimuli,
whereas multiple modalities (e.g. electrical, pressure) can
give more information about pain perception of the
individual patient. Conclusions can be drawn only for
the development of secondary hyperalgesia 1 year after
remifentanil administration measured with thermal
thresholds. For instance, no data are available about
mechanical or electrical tests around the wound.
Conclusion
Despite the unfavourable effects of remifentanil vs.
fentanyl on chronic thoracic pain after 3 months, it is
positive that no significant effect of remifentanil on
thermal pain sensitivity and chronic thoracic pain was
found 1 year after cardiac surgery. Additional predictors
of altered pain sensitivity could not be identified. Again,
this study contributes to the body of literature that
concludes that chronic postoperative pain is multimodal
and it remains difficult to predict which patients are at
risk for chronic postoperative pain. However, this study
showed again a high incidence of chronic thoracic pain
after cardiac surgery, which is known to have a consider-
able impact on QoL. Investing in the prevention and
early detection of chronic postsurgical pain is the next
logical step.
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